2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Cell Expansion, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Other Pathogens, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6255 Real-world time to next treatment or death and overall survival of first-line 2nd generation covalent Bruton tyrosine kinase inhibitor monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma using administrative claims

Joanna M Rhodes, MD, MSCE, Victoria Otero, MD2, Daniel Huang, PharmD, MPH3, Julia Ma, MPH4, Debbie Adkins, PhD, CStat5, Dipen Patel, PhD6
1 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
2 AstraZeneca, Gaithersburg, Maryland, United States
3 AstraZeneca, Gaithersburg, Maryland, United States
4 AstraZeneca, Mississauga, Ontario, Canada
5 AstraZeneca, Cambridge, United Kingdom
6 AstraZeneca, Gaithersburg, Maryland, United States

Background: Acalabrutinib and zanubrutinib are 2nd generation covalent Bruton tyrosine kinase (cBTKi) used as standard first-line (1L) treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In administrative claims analysis, real-world time to next treatment or death (rwTTNTd) is commonly used as a proxy of treatment effectiveness and disease progression. rwTTNTd interpretation is particularly nuanced for cBTKi in CLL/SLL, where multiple treatment options exist, including continuous monotherapy, planned combination therapy, and fixed-duration regimens. This study compared the real-world effectiveness of acalabrutinib versus zanubrutinib monotherapy in patients with CLL/SLL using standardized definitions of subsequent treatment intended to support consistent classification of next-treatment events.

Methods: Adults with CLL/SLL and ≥1 claim for 1L acalabrutinib or zanubrutinib monotherapy between January 1, 2023, and September 30, 2025, were identified in the Optum Clinformatics Data Mart database. The index date was the first observed claim for cBTKi. Patients required ≥6 months of continuous enrollment before treatment initiation and an index date ≥3 months before the database-specific cutoff. In the primary analysis, a qualifying next-treatment event was defined as initiation of a guideline recommended CLL/SLL drug (bendamustine, chlorambucil, duvelisib, idelalisib, lenalidomide, pirtobrutinib, or venetoclax) >60 days after the index date. Outcomes included rwTTNTd and overall survival (OS). Inverse probability of treatment weighting (IPTW) was used to adjust for baseline and disease characteristics, such as index year, age, and National Cancer Institute (NCI) comorbidity index.  Weighted landmark treatment and survival probabilities at 12 months were estimated using Kaplan-Meier methods. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox proportional hazard models. Two sensitivity analyses classified 1) an in-class cBTKi switch and 2) anti-CD20 monotherapy as a qualifying next-treatment event. 

Results: Among 7,342 patients who have at ≥1 claim of cBTKi in the study period, 1,758 met the study criteria (acalabrutinib, n=1,196; zanubrutinib n=562). After IPTW, measured baseline characteristics were balanced across cohorts. Mean age was approximately 75 years, 38% were female, >90% had Medicare coverage, and mean comorbidity index was 1.1 and 1.0 among the acalabrutinib and zanubrutinib cohorts, respectively. Baseline atrial fibrillation was reported in 11.5% and 13.2%, arrythmia in 13.0% and 15.3%, hypertension in 57.0% and 60.5%, bleeding in 4.3% and 6.0%, and infection in 15.9% and 13.7% of the acalabrutinib and zanubrutinib cohorts, respectively. Median follow-up was 17.0 months for acalabrutinib and 16.4 months for zanubrutinib. At 12 months, IPTW-adjusted estimates for acalabrutinib versus zanubrutinib were: rwTTNTd 87% (95% CI, 84.3%–89.7%) vs. 85.2% (82.1%–88.3%); OS 93.1% (91.1%–95.1%) vs 90.1% (87.5%–92.7%). HRs (acalabrutinib vs zanubrutinib) were 0.86 (95% CI, 0.67–1.11) for rwTTNTd and 0.73 (0.54–1.00) for OS. Median rwTTNTd and OS were not reached. In sensitivity analyses, no statistically significant difference in rwTTNTd was observed when in-class BTKi switching (HR, 1.02; 95% CI, 0.80-1.29) or anti-CD20 monotherapy (HR, 0.99; 95% CI, 0.77-1.26) was classified as qualifying next-treatment event.

Conclusion: In this administrative claims-based study of patients with CLL/SLL initiating 1L cBTKi monotherapy, acalabrutinib and zanubrutinib demonstrated comparable real world effectiveness, as demonstrated by rwTTNTd and OS. While these findings provide important real-world insight, electronic health records-based studies with longer follow-up and detailed clinical information are needed to more accurately capture disease progression and confirm these observations.

Joanna M Rhodes, MD, MSCE: Acrotech - Research Funding; Acerta - Research Funding; Janssen - Research Funding; Beigene - Research Funding; Merck - Research Funding; Oncternal - Research Funding; AstraZeneca - Research Funding; Epizyme - Research Funding; ADC Therapeutics - Research Funding; Loxo Oncology - Research Funding; Velosbios - Research Funding; Abbvie - Research Funding; BeOne - Research Funding; Johnson and Johnson - Research Funding; Morphosys - Consultancy (Includes expert testimony); Loxo Oncology - Consultancy (Includes expert testimony); Johnson and Johnson - Consultancy (Includes expert testimony); GenMab - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Epizyme - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); SeaGen - Consultancy (Includes expert testimony)